Conv. Plasma
Nigella Sativa
Peg.. Lambda

All lactoferrin studies
Meta analysis
Home COVID-19 treatment researchLactoferrinLactoferrin (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Symp. case -59% Improvement Relative Risk Case -23% Lactoferrin  LF-COVID  Prophylaxis  DB RCT Is prophylaxis with lactoferrin beneficial for COVID-19? Double-blind RCT 209 patients in Peru (October 2020 - February 2021) More symptomatic cases with lactoferrin (not stat. sig., p=0.34) Navarro et al., BioMetals, December 2022 Favors lactoferrin Favors control

Bovine lactoferrin for the prevention of COVID-19 infection in health care personnel: a double-blinded randomized clinical trial (LF-COVID)

Navarro et al., BioMetals, doi:10.1007/s10534-022-00477-3, LF-COVID, NCT04526821
Dec 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Early terminated low-risk patient prophylaxis RCT in Peru, showing no significant difference in cases with lactoferrin. There were no moderate or severe cases.
risk of symptomatic case, 58.7% higher, RR 1.59, p = 0.34, treatment 11 of 104 (10.6%), control 7 of 105 (6.7%).
risk of case, 23.4% higher, RR 1.23, p = 0.65, treatment 11 of 104 (10.6%), control 9 of 105 (8.6%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Navarro et al., 7 Dec 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Peru, peer-reviewed, median age 37.0, 14 authors, study period October 2020 - February 2021, trial NCT04526821 (history) (LF-COVID).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperLactoferrinAll
Bovine lactoferrin for the prevention of COVID-19 infection in health care personnel: a double-blinded randomized clinical trial (LF-COVID)
Rafaella Navarro, Jose Luis Paredes, Lourdes Tucto, Carlos Medina, Eddie Angles-Yanqui, Juan Carlos Nario, Jorge Ruiz-Cabrejos, Juan Luis Quintana, Kevin Turpo-Espinoza, Fernando Mejia-Cordero, Meylin Aphang-Lam, Jorge Florez, Gabriel Carrasco-Escobar, Theresa Jean Ochoa
BioMetals, doi:10.1007/s10534-022-00477-3
suspected episodes. A serological test was obtained from all participants at the end of the intervention. The main outcome included symptomatic and asymptomatic cases. A sub-analysis explored the time to symptomatic infection. Secondary outcomes were the severity, frequency, and duration of symptomatic infection. The study was prematurely cancelled due to the availability of vaccines against SARS-CoV-2 in Peru. 209 participants were enrolled and randomized, 104 received bLF and 105 placebo. SARS-CoV-2 infection occurred in 11 (10.6%) participants assigned to bLF and in 9 (8.6%) participants assigned to placebo without significant differences (Incidence Rate Ratio = 1.23, 95%CI 0.51-3.06, p-value = 0.64). There was no significant effect of bLF on time to symptomatic infection (Hazard Ratio = 1.61, 95%CI 0.62-4.19, p-value = 0.3). There were no significant Abstract Lactoferrin (LF) has in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to determine the effect of bovine lactoferrin (bLF) in the prevention of SARS-CoV-2 infection in health care personnel. A randomized, double-blinded, placebo-controlled clinical trial was conducted in two tertiary hospitals that provide care to patients with SARS-CoV-2 infection in Lima, Peru. Daily supplementation with 600 mg of enteral bLF versus placebo for 90 days was compared. Participants were weekly screened for symptoms suggestive of SARS-CoV-2 infection and molecular testing was performed on
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s10534-022-00477-3. Duration and prevalence of secondary outcomes are shown in Table 3 . The most common symptoms among the 18 symptomatic SARS-CoV-2 infections were: cough in 11 participants (61%), nasal secretion in 10 (56%), headache in 8 (44%), and sore throat in 8 (44%). The proportion of patients who developed fever during the study period and the duration of fever were slightly lower t in bLF than in the placebo group, but not significant different (Table 3 ).
Alugupalli, Kalfas, Degradation of lactoferrin by periodontitis-associated bacteria, FEMS Microbiol Lett, doi:10.1111/j.1574-6968.1996.tb08579.x
Beljaars, Van Der Strate, Bakker, Reker-Smit, Van Loenen-Weemaes et al., Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo, Antivir Res, doi:10.1111/j.1574-6968.1996.tb08579.x
Berlutti, Schippa, Morea, Sarli, Perfetto et al., Lactoferrin downregulates proinflammatory cytokines upexpressed in intestinal epithelial cells infected with invasive or noninvasive Escherichia coli strains, Biochem Cell Biol
Berthon, Williams, Williams, Wood, Effect of lactoferrin supplementation on inflammation, immune function, and prevention of respiratory tract infections in humans: a systematic review and meta-analysis, Adv Nutr, doi:10.1093/advances/nmac047
Biase, Pietrantoni, Tinari, Siciliano, Valenti et al., Heparin-interacting sites of bovine lactoferrin are involved in anti-adenovirus activity, J Med Virol
Chang, Ng, Sun, Lactoferrin as potential preventative and adjunct treatment for COVID-19, Int J Antimicrob Agents
Chen, Chai, Li, Zhang, Xie et al., Effect of bovine lactoferrin from iron-fortified formulas on diarrhea and respiratory tract infections of weaned infants in a randomized controlled trial, Nutrition
Drobni, Näslund, Evander, Lactoferrin inhibits human papillomavirus binding and uptake in vitro, Antivir Res
Figueroa, Bottazzi, Hotez, Batista, Ergonul et al., Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics, Lancet
Hanson, Caliendo, Arias, Englund, Lee et al., ica guidelines on the diagnosis of COVID-19, Infectious Diseases Society of Amer
Harris, Taylor, Minor, Elliott, Fernandez et al., The REDCap consortium: building an international community of software platform partners, J Biomed Inform
Harris, Taylor, Thielke, Payne, Gonzalez et al., Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform
Ishikawa, Awano, Fukui, Sasaki, Kyuwa, The protective effects of lactoferrin against murine norovirus infection through inhibition of both viral attachment and replication, Biochem Biophys Res Commun
Lang, Yang, Deng, Liu, Yang et al., Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans, PLoS ONE
Legrand, Overview of lactoferrin as a natural immune modulator, J Pediatr
Lizzi, Carnicelli, Clarkson, Bovine lactoferrin and its tryptic peptides: antibacterial activity against different species, Appl Biochem Microbiol, doi:10.1134/S0003683816040116
Marchetti, Trybala, Superti, Johansson, Bergström, Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans, Virology
Oda, Wakabayashi, Tanaka, Yamauchi, Sugita et al., Effects of lactoferrin on infectious diseases in Japanese summer: a randomized, double-blinded, placebo-controlled trial, J Microbiol Immunol Infect, doi:10.1016/j.jmii.2020.02.010
Reghunathan, Jayapal, Hsu, Chng, Tai et al., Expression profile of immune response genes in patients with severe acute respiratory syndrome, BMC Immunol
Serrano, Kochergina, Albors, Diaz, Oroval et al., Liposomal lactoferrin as potential preventative and cure for COVID-19, Int J Res Health Sci
Shah, Wood, Gribben, Caldwell, Bishop et al., Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study, doi:10.1136/bmj.m3582
Superti, Siciliano, Rega, Giansanti, Valenti et al., Involvement of bovine lactoferrin metal saturation, sialic acid and protein fragments in the inhibition of rotavirus infection, Biochim Biophys Acta
Vitetta, Coulson, Beck, Gramotnev, Du et al., The clinical efficacy of a bovine lactoferrin/whey protein Ig-rich fraction (Lf/IgF) for the common cold: a double blind randomized study, Complement Ther Med
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop